Melatonin Suppresses Ferroptosis Induced by High Glucose via Activation of the Nrf2/HO-1 Signaling Pathway in Type 2 Diabetic Osteoporosis

被引:317
|
作者
Ma, Hongdong [1 ]
Wang, Xindong [1 ]
Zhang, Weilin [2 ]
Li, Haitian [1 ]
Zhao, Wei [2 ]
Sun, Jun [3 ]
Yang, Maowei [1 ]
机构
[1] China Med Univ, Hosp 1, Dept Orthoped, Shenyang, Liaoning, Peoples R China
[2] China Med Univ, Hosp 4, Dept Orthoped, Shenyang, Liaoning, Peoples R China
[3] Jinzhou Med Univ, Hosp 3, Dept Orthoped, Jinzhou, Liaoning, Peoples R China
关键词
BONE-MINERAL DENSITY; FRACTURE RISK; INDUCED APOPTOSIS; MC3T3-E1; CELLS; IRON OVERLOAD; AUTOPHAGY; PROTECTS; ACID; PI3K/AKT; DEATH;
D O I
10.1155/2020/9067610
中图分类号
Q2 [细胞生物学];
学科分类号
071009 ; 090102 ;
摘要
Ferroptosis is recently identified, an iron- and reactive oxygen species- (ROS-) dependent form of regulated cell death. This study was designed to determine the existence of ferroptosis in the pathogenesis of type 2 diabetic osteoporosis and confirm that melatonin can inhibit the ferroptosis of osteoblasts through activating Nrf2/HO-1 signaling pathway to improve bone microstructure in vivo and in vitro. We treated MC3T3-E1 cells with different concentrations of melatonin (1, 10, or 100 mu M) and exposed them to high glucose (25.5 mM) for 48 h in vitro. Our data showed that high glucose can induce osteoblast cytotoxicity and the accumulation of lipid peroxide, the mitochondria of osteoblast show the same morphology changes as the erastin treatment group, and the expression of ferroptosis-related proteins glutathione peroxidase 4 (GPX4) and cystine-glutamate antiporter (SLC7A11) is downregulated, but these effects were reversed by ferroptosis inhibitor ferrastatin-1 and iron chelator deferoxamine (DFO). Furthermore, western blot and real-time polymerase chain reaction were used to detect the expression levels of nuclear factor erythroid 2-related factor 2 (Nrf2) and heme oxygenase-1 (HO-1); osteogenic capacity was evaluated by alizarin red S staining and the expression of osteoprotegerin, osteocalcin, and alkaline phosphatase; the results showed that the expression levels of these proteins in osteoblasts with 1, 10, or 100 mu M melatonins were significantly higher than the high glucose group, but after using Nrf2-SiRNA interference, the therapeutic effect of melatonin was significantly inhibited. We also performed in vivo experiments in a diabetic rat model treated with two concentrations of melatonin (10, 50 mg/kg). Dynamic bone histomorphometry and micro-CT were used to observe the rat bone microstructure, and the expression of GPX4 and Nrf2 was determined by immunohistochemistry. Here, we first report that high glucose induces ferroptosis via increased ROS/lipid peroxidation/glutathione depletion in type 2 diabetic osteoporosis. More importantly, melatonin significantly reduced the level of ferroptosis and improved the osteogenic capacity of MC3T3-E1 through activating the Nrf2/HO-1 pathway in vivo and in vitro.
引用
收藏
页数:18
相关论文
共 50 条
  • [1] Metformin suppresses Oxidative Stress induced by High Glucose via Activation of the Nrf2/HO-1 Signaling Pathway in Type 2 Diabetic Osteoporosis
    Chen, Bohao
    He, Qi
    Yang, Junzheng
    Pan, Zhaofeng
    Xiao, Jiacong
    Chen, Weijian
    Chi, Weijin
    Li, Miao
    Li, Shaocong
    Zeng, Jiaxu
    Chen, Chuyi
    Wang, FanChen
    Pang, Xinyuan
    Yi, Yanzi
    Tu, Haitao
    Wang, Haibin
    Chen, Peng
    LIFE SCIENCES, 2023, 312
  • [2] Melatonin suppresses ferroptosis via activation of the Nrf2/HO-1 signaling pathway in the mouse model of sepsis-induced acute kidney injury
    Qiu, Weihuang
    An, Sheng
    Wang, Tingjie
    Li, Jiaxin
    Yu, Binmei
    Zeng, Zhenhua
    Chen, Zhongqing
    Lin, Bo
    Lin, Xianzhong
    Gao, Youguang
    INTERNATIONAL IMMUNOPHARMACOLOGY, 2022, 112
  • [3] Maresin1 Suppresses High-Glucose-Induced Ferroptosis in Osteoblasts via NRF2 Activation in Type 2 Diabetic Osteoporosis
    Zhang, Zhanwei
    Ji, Chonghao
    Wang, Ya-Nan
    Liu, Shiyue
    Wang, Maoshan
    Xu, Xin
    Zhang, Dongjiao
    CELLS, 2022, 11 (16)
  • [4] β-cryptoxanthin suppresses oxidative stress via activation of the Nrf2/HO-1 signaling pathway in diabetic kidney disease
    Ke, Jingjing
    Zang, Hualong
    Liu, Yang
    Teng, Qiuping
    Hua, Jiao
    Peng, Dan
    Wang, Ping
    FRONTIERS IN PHARMACOLOGY, 2024, 15
  • [5] β-Caryophyllene suppresses ferroptosis induced by cerebral ischemia reperfusion via activation of the NRF2/HO-1 signaling pathway in MCAO/R rats
    Hu, Qingwen
    Zuo, Tianrui
    Deng, Ling
    Chen, Sha
    Liu, Shengwei
    Liu, JingDong
    Wang, Xuan
    Fan, Xiaomei
    Dong, Zhi
    PHYTOMEDICINE, 2022, 102
  • [6] Aryl piperazine suppresses cataractogenesis in a diabetic rat model via Nrf2/HO-1 signaling pathway
    Wang, Xiu
    Tian, Congcong
    Zhao, Chunning
    TROPICAL JOURNAL OF PHARMACEUTICAL RESEARCH, 2020, 19 (11) : 2317 - 2322
  • [7] Fructus Ligustri Lucidi inhibits ferroptosis in ovariectomy-induced osteoporosis in rats via the Nrf2/HO-1 signaling pathway
    Li, Pei
    Wang, Yuhan
    Yan, Qiqi
    Yang, Ying
    Zhu, Ruyuan
    Ma, Jiayi
    Chen, Yanjing
    Liu, Haixia
    Zhang, Zhiguo
    BIOMEDICAL REPORTS, 2024, 20 (02)
  • [8] Melatonin suppresses cisplatin-induced nephrotoxicity via activation of Nrf-2/HO-1 pathway
    Kilic, Ulkan
    Kilic, Ertugrul
    Tuzcu, Zeynep
    Tuzcu, Mehmet
    Ozercan, Ibrahim H.
    Yilmaz, Okkes
    Sahin, Fikrettin
    Sahin, Kazim
    NUTRITION & METABOLISM, 2013, 10
  • [9] Melatonin suppresses cisplatin-induced nephrotoxicity via activation of Nrf-2/HO-1 pathway
    Ulkan Kilic
    Ertugrul Kilic
    Zeynep Tuzcu
    Mehmet Tuzcu
    Ibrahim H Ozercan
    Okkes Yilmaz
    Fikrettin Sahin
    Kazim Sahin
    Nutrition & Metabolism, 10
  • [10] Urolithin A ameliorates diabetic retinopathy via activation of the Nrf2/HO-1 pathway
    Xu, Zepeng
    Li, Songtao
    Li, Kunmeng
    Wang, Xiaoyu
    Li, Xiaojie
    An, Meixia
    Yu, Xiaoyi
    Long, Xinguang
    Zhong, Ruiying
    Liu, Qiuhong
    Wang, Xiaochuan
    Yang, Yan
    Tian, Ni
    ENDOCRINE JOURNAL, 2022, 69 (08) : 971 - 982